BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2781538)

  • 1. An eight year experience with gradually longer interval postremission therapy for adults with acute leukemia.
    Kawamura S; Mikami T; Sawada Y; Chiba Y; Yoshida Y
    Tohoku J Exp Med; 1989 May; 158(1):17-24. PubMed ID: 2781538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An intensification therapy of adults acute leukemia].
    Kawamura S; Kawarada R; Tsushima Y; Sawada Y; Yoshida Y; Chiba Y; Yamaya T; Kawatsu S; Aizawa M; Segawa M
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):83-7. PubMed ID: 2643396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study.
    Ogata K; An E; Kamikubo K; Yokose N; Tamura H; Yamada T; Gomi S; Dan K; Nomura T
    Stem Cells; 1998; 16(4):280-7. PubMed ID: 9708450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative evaluation of combined chemotherapeutic regimens in acute non-lymphocytic leukemia].
    Sasaki H; Maekawa I; Kawamura S; Miyake T
    Hokkaido Igaku Zasshi; 1983 May; 58(3):271-8. PubMed ID: 6194091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The curative treatment of adult acute nonlymphocytic leukemia].
    Uzuka Y; Saito Y
    Rinsho Ketsueki; 1989 Aug; 30(8):1163-6. PubMed ID: 2601025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature.
    Yokose N; Ogata K; Ito T; Miyake K; An E; Inokuchi K; Yamada T; Gomi S; Tanabe Y; Ohki I
    Ann Hematol; 1993 Feb; 66(2):67-70. PubMed ID: 8383541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
    Yoshida M; Suda K; Tsuboyama A; Sasaki R; Kitagawa S; Kano Y; Muto Y; Takaku F; Sakamoto S; Miura Y
    Eur J Haematol; 1989 Jul; 43(1):1-6. PubMed ID: 2767238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
    Ohno R; Kato Y; Nagura E; Murase T; Okumura M; Yamada H; Ogura M; Minami S; Suzuki H; Morishima Y
    J Clin Oncol; 1986 Dec; 4(12):1740-7. PubMed ID: 3465875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
    Sampi K; Sakurai M; Kaneko Y; Hattori M
    Oncology; 1986; 43(1):18-22. PubMed ID: 3455751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
    Nagura E; Kimura K; Yamada K; Ohta K; Maekawa T; Takaku F; Uchino H; Masaoka T; Amaki I; Kawashima K
    Cancer Chemother Pharmacol; 1994; 34(1):23-9. PubMed ID: 8174198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer curable by chemotherapy: acute myelogenous leukemia].
    Ohno R; Tanimoto M; Morishita Y; Morishima Y; Saito H; Yokomaku S; Nagai T; Kodera Y; Minami S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1329-34. PubMed ID: 2730046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
    Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.
    Fujisawa S; Maruta A; Motomura S; Fukawa H; Kanamori H; Ogawa K; Matsuzaki M; Miyashita H; Harano H; Murata T; Sakai R; Mohri H; Kodama F; Okubo T
    Leuk Lymphoma; 1998 Mar; 29(1-2):161-70. PubMed ID: 9638985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.